- Home
- NMIH vs DNLI Comparison
NMIH vs DNLI Comparison
Compare NMIH & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMIH | DNLI |
|---|---|---|
| Founded | 2011 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.6B |
| IPO Year | 2013 | 2017 |
Fundamental Metrics
Financial Performance| Metric | NMIH | DNLI |
|---|---|---|
| Price | $41.05 | $20.95 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 12 |
| Target Price | ★ $42.60 | $30.82 |
| AVG Volume (30 Days) | 532.2K | ★ 1.7M |
| Earning Date | 02-10-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 9.56 | N/A |
| EPS | ★ 4.79 | N/A |
| Revenue | ★ $692,208,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.79 | $3,897.53 |
| P/E Ratio | $8.57 | ★ N/A |
| Revenue Growth | ★ 8.86 | N/A |
| 52 Week Low | $31.90 | $10.57 |
| 52 Week High | $43.20 | $23.79 |
Technical Indicators
Market Signals| Indicator | NMIH | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 64.56 | 57.16 |
| Support Level | $37.83 | $19.76 |
| Resistance Level | $38.70 | $23.77 |
| Average True Range (ATR) | 0.95 | 1.40 |
| MACD | 0.38 | 0.00 |
| Stochastic Oscillator | 94.69 | 56.98 |
Price Performance
Historical ComparisonAbout NMIH NMI Holdings Inc.
NMI Holdings Inc through its subsidiaries provides private mortgage guaranty insurance. The company offers mortgage insurance, reinsurance on loans, and outsourced loan review services to mortgage loan originators. It serves national and regional mortgage banks, money center banks, credit unions, community banks, builder-owned mortgage lenders, Internet-sourced lenders, and other non-bank lenders. It protects lenders and investors from default-related losses on a portion of the unpaid principal balance of a covered mortgage.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.